Rapid point-of-care BioLytical offers INSTI rapid HIV tests with results in as little as 60 seconds, presenting a strong value proposition for urgent diagnostics in clinics, urgent care, mobile units, and outreach programs.

Expansion opportunities Recent product expansions include INSTI multiplex HIV-1/2 and syphilis, with ongoing development of HCV tests and self-test versions, signaling cross-selling potential to existing HIV customers and new markets needing dual or multi-disease rapid testing.

Global regulatory reach With FDA, Health Canada, and CE approvals, BioLytical is well-positioned to scale in regulated markets and pursue international tenders, partnerships, and donations through NGO collaborations.

Strategic partnerships Existing collaborations and NGO donations (Coalition PLUS) indicate a channel for field deployment, government programs, and public health initiatives that can drive procurement agreements and volume opportunities.

Growth signals Recognition as a fastest-growing BC company and a history of awards, coupled with a revenue range in the low to mid millions, suggests room to upsell into larger health systems while maintaining a niche focus on rapid diagnostics.